Lipocine announces LPCN 2101 abstracts accepted for AES 2025 annual meeting

Lipocine Inc.

Two LPCN 2101 abstracts accepted for poster presentation at AES 2025 (Dec 5-9, Atlanta).
Abstracts cover oral toxicokinetics and clinical pharmacokinetics/tolerability of LPCN 2101.
LPCN 2101 is a GABA-A receptor modulating neuroactive steroid for potential treatment of epilepsy.
Data remain embargoed until November 24, 2025, per AES policy.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.